Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
作者: Shen ZGillen MMiner JNBucci GWilson DMHall JW
刊名: Drug Design, Development and Therapy, 2017, Vol.Volume 11 , pp.2077-2086
来源数据库: Directory of Open Access Journals
关键词: PharmacokineticsPharmacodynamicsSelective uric acid reabsorption inhibitorSerum urateUrinary uric acid
原始语种摘要: Zancong Shen,1 Michael Gillen,2 Jeffrey N Miner,1 Gail Bucci,1 David M Wilson,1 Jesse W Hall1 1Ardea Biosciences, Inc., San Diego, CA, 2AstraZeneca, Gaithersburg, MD, USA Purpose: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of verinurad in healthy adult males.Subjects and methods: This was a Phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study. Panels of eight male subjects received a single oral dose of verinurad or placebo in either a fasted or fed state; panels of 10–12 male subjects received ascending doses of once-daily verinurad or placebo in...
全文获取路径: PDF下载  DOAJ  (合作)
影响因子:3.486 (2012)

  • reabsorption 重吸收
  • tolerability 可容许性
  • adult 成体
  • healthy 健康的
  • urate 尿酸盐
  • inhibitor 抑制剂
  • selective 选择性的
  • dosing 配量
  • laboratory 实验室
  • urinary 尿的